OCUL — OCULAR THERAPEUTIX, INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1393434 ·
Last close
$7.66
Market Cap
$1.68B
52W High
$16.44
52W Low
$6.23
ADV30
3,064,474
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 13,475,000 | 11,464,000 | -82,109,000 | -78,763,000 | 671,317,000 | 598,641,000 | 151,276,000 |
| Mar 2026 | 10,785,000 | 9,456,000 | -93,340,000 | -88,612,000 | 732,529,000 | 666,699,000 | 150,955,000 |
| Dec 2025 | 13,250,000 | 11,656,000 | -69,760,000 | -64,654,000 | 808,057,000 | 737,060,000 | 153,747,000 |
| Sep 2025 | 14,544,000 | 12,770,000 | -68,698,000 | -69,418,000 | 410,882,000 | 344,772,000 | 152,653,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-238,239,000
Investing CF
$-16,861,000
Financing CF
$462,607,000
CapEx
$-16,861,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.42
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,324,398,000
Inventory
$3,826,000
Receivables
$30,261,000
ST Investments
—
EBIT TTM
$-290,044,000
Pretax Income TTM
$-301,447,000
Interest Exp TTM
$11,403,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$52,055,000
EBITDA
$-308,457,984
Free Cash Flow
$-159,248,992
Enterprise Value
$1,784,512,512
Total Cash
$598,641,024
Total Debt
$79,383,000
Shares Out
219,615,868
Trailing EPS
$-1.40
Book Value
$2.37
ROE
-73.0%
ROA
-35.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 51,951,000 | -270,017,000 | -265,939,000 | 808,057,000 | 153,747,000 | 654,310,000 | -204,883,000 |
| Dec 2024 | 63,723,000 | -171,781,000 | -193,506,000 | 457,935,000 | 142,591,000 | 315,344,000 | -134,677,000 |
| Dec 2023 | 58,443,000 | -82,382,000 | -80,736,000 | 252,060,000 | 160,929,000 | 91,131,000 | -70,234,000 |
| Dec 2022 | 51,494,000 | -78,654,000 | -71,038,000 | 149,289,000 | 113,910,000 | 35,379,000 | -59,603,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.45
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $7.00 · spot: $7.66 · call volume: 2,496 · put volume: 237
Expected Move to 2026-10-16:
±$1.01
(13.19%) —
implied range
$6.65 –
$8.67
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ETON | Eton Pharmaceuticals, Inc. | $1.69B | $59.18 | — |
| NBTX | Nanobiotix S.A. | $1.66B | $32.60 | — |
| STOK | Stoke Therapeutics, Inc. | $1.65B | $25.50 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.72B | $74.83 | — |
| GHRS | GH Research PLC | $1.61B | $23.42 | — |
News headlines (Yahoo Finance, 1h cache)
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
2026-09-28 17:15 · Yahoo
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
2026-09-23 21:38 · Yahoo
Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?
2026-09-23 10:32 · Yahoo
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
2026-09-23 03:02 · Yahoo
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-18 11:00 · Yahoo
Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs
2026-09-03 11:06 · Yahoo
Why Ocular Therapeutix (OCUL) Is Up 10.4% After Q2 Beat And AXPAXLI Phase 3 Timeline Update
2026-08-22 14:08 · Yahoo
Ocular Therapeutix (OCUL) Could Be 59% Undervalued Following Earnings Beat And AXPAXLI Progress
2026-08-22 06:10 · Yahoo
Ocular Therapeutix (OCUL) Stock Fair Value Edges Higher After Analyst Target Increases
2026-08-22 01:12 · Yahoo
Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)
2026-08-21 19:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.